Fisher Asset Management LLC Purchases 403 Shares of Amgen Inc. (NASDAQ:AMGN)


Share on StockTwits

Fisher Asset Management LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the first quarter, Holdings Channel reports. The firm owned 72,818 shares of the medical research company’s stock after acquiring an additional 403 shares during the period. Fisher Asset Management LLC’s holdings in Amgen were worth $18,118,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Amgen during the fourth quarter valued at about $1,302,778,000. Morgan Stanley grew its holdings in Amgen by 13.8% during the fourth quarter. Morgan Stanley now owns 9,745,556 shares of the medical research company’s stock worth $2,240,698,000 after buying an additional 1,179,665 shares in the last quarter. Boston Partners grew its holdings in Amgen by 4,644.8% during the fourth quarter. Boston Partners now owns 972,579 shares of the medical research company’s stock worth $223,616,000 after buying an additional 952,081 shares in the last quarter. FIL Ltd boosted its position in Amgen by 199.4% in the fourth quarter. FIL Ltd now owns 853,277 shares of the medical research company’s stock worth $196,185,000 after purchasing an additional 568,324 shares during the last quarter. Finally, Beutel Goodman & Co Ltd. boosted its position in Amgen by 67.0% in the fourth quarter. Beutel Goodman & Co Ltd. now owns 1,028,961 shares of the medical research company’s stock worth $236,578,000 after purchasing an additional 412,976 shares during the last quarter. 75.23% of the stock is currently owned by institutional investors and hedge funds.

Shares of AMGN opened at $245.38 on Tuesday. The company has a debt-to-equity ratio of 3.12, a current ratio of 2.28 and a quick ratio of 1.88. The stock has a market cap of $141.29 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. Amgen Inc. has a 1-year low of $210.28 and a 1-year high of $276.69. The firm has a fifty day moving average price of $248.86 and a 200 day moving average price of $236.11.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Monday, April 26th. The medical research company reported $3.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.05 by ($0.35). Amgen had a net margin of 29.42% and a return on equity of 95.55%. The firm had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $6.30 billion. During the same period in the previous year, the company posted $4.17 EPS. The business’s quarterly revenue was down 4.2% on a year-over-year basis. As a group, equities analysts expect that Amgen Inc. will post 16.15 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Monday, May 17th will be paid a dividend of $1.76 per share. The ex-dividend date of this dividend is Friday, May 14th. This represents a $7.04 dividend on an annualized basis and a yield of 2.87%. Amgen’s dividend payout ratio (DPR) is 47.50%.

A number of brokerages recently issued reports on AMGN. Evercore ISI reissued a “buy” rating on shares of Amgen in a report on Thursday, April 29th. Robert W. Baird reiterated a “sell” rating on shares of Amgen in a research report on Thursday, April 29th. BMO Capital Markets dropped their price objective on Amgen from $301.00 to $296.00 and set an “outperform” rating for the company in a report on Wednesday, April 28th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $215.00 target price on shares of Amgen in a research note on Wednesday, April 28th. Finally, Royal Bank of Canada reduced their price objective on Amgen from $220.00 to $217.00 and set a “sector perform” rating for the company in a research report on Wednesday, April 28th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. Amgen has an average rating of “Hold” and an average target price of $255.62.

In related news, EVP Jonathan P. Graham sold 11,110 shares of Amgen stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $236.51, for a total value of $2,627,626.10. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronald D. Sugar sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, April 14th. The shares were sold at an average price of $249.98, for a total transaction of $249,980.00. Following the transaction, the director now directly owns 16,927 shares in the company, valued at approximately $4,231,411.46. The disclosure for this sale can be found here. Insiders have sold a total of 14,360 shares of company stock worth $3,407,034 over the last quarter. 0.36% of the stock is currently owned by insiders.

About Amgen

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.

Featured Article: Are we seeing the beginning of a new bubble?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.